222 related articles for article (PubMed ID: 6332379)
1. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
Mulé JJ; Shu S; Schwarz SL; Rosenberg SA
Science; 1984 Sep; 225(4669):1487-9. PubMed ID: 6332379
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
Fukuta K; Sone S; Kitahara M; Okada M; Ogura T
Jpn J Cancer Res; 1989 Jun; 80(6):562-7. PubMed ID: 2503476
[TBL] [Abstract][Full Text] [Related]
3. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo.
Bubeník J; Indrová M
Cancer Immunol Immunother; 1987; 24(3):269-71. PubMed ID: 3496154
[TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases.
Yamasaki K; Sone S; Yamashita T; Ogura T
Cancer Immunol Immunother; 1989; 29(2):87-92. PubMed ID: 2785852
[TBL] [Abstract][Full Text] [Related]
6. In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models.
Eggermont AM; Sugarbaker PH; Marquet RL; Jeekel J
Cancer Immunol Immunother; 1988; 26(1):23-30. PubMed ID: 3257900
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.
Fagan EA; Eddleston AL
Gut; 1987 Feb; 28(2):113-6. PubMed ID: 3549471
[No Abstract] [Full Text] [Related]
8. Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type.
Kedar E; Ben-Aziz R; Epstein E; Leshem B
Cancer Immunol Immunother; 1989; 29(1):74-8. PubMed ID: 2785003
[TBL] [Abstract][Full Text] [Related]
9. Recruitment of inflammatory cells to a tumor deposit potentiates the immunotherapeutic effects of interleukin-2.
Steller EP; Eggermont AM; Matthews W; Sugarbaker PH
Cancer Immunol Immunother; 1986; 23(3):165-8. PubMed ID: 3491680
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report.
Bubeník J; Perlmann P; Indrová M; Símová J; Jandlová T; Neuwirt J
Cancer Immunol Immunother; 1983; 14(3):205-6. PubMed ID: 6601512
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer.
Kradin RL; Boyle LA; Preffer FI; Callahan RJ; Barlai-Kovach M; Strauss HW; Dubinett S; Kurnick JT
Cancer Immunol Immunother; 1987; 24(1):76-85. PubMed ID: 3493073
[TBL] [Abstract][Full Text] [Related]
12. Tumour inhibitory effects of TCGF/IL-2/-containing preparations.
Bubeník J; Indrová M; Perlmann P; Berzins K; Mach O; Kraml J; Toulcová A
Cancer Immunol Immunother; 1985; 19(1):57-61. PubMed ID: 3872165
[TBL] [Abstract][Full Text] [Related]
13. Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J; Liu X; Tian HX; Chen Y; Cao Y; Zeng J; Liu YC; Chen Y; Gao Y; Yin JY; Wang PY
Clin Transl Med; 2024 Apr; 14(4):e1656. PubMed ID: 38664597
[TBL] [Abstract][Full Text] [Related]
14. A pilot study on the safety and efficacy of neoadjuvant chemo‑adoptive immunotherapy for locally advanced rectal cancer.
Okazawa Y; Kamigaki T; Sugimoto K; Yamada T; Yoshida Y; Okada S; Ibe H; Oguma E; Iwai T; Matsuda A; Yamada T; Hasegawa S; Goto S; Takimoto R; Sakamoto K
Oncol Lett; 2024 Mar; 27(3):101. PubMed ID: 38298433
[TBL] [Abstract][Full Text] [Related]
15. Adoptive cell therapy for cancer treatment.
Du S; Yan J; Xue Y; Zhong Y; Dong Y
Exploration (Beijing); 2023 Aug; 3(4):20210058. PubMed ID: 37933232
[TBL] [Abstract][Full Text] [Related]
16. T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancer.
Xie X; Li X; Liu G; Zhao H; Zhou Z; Xiong S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11561-11570. PubMed ID: 37402965
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocyte.
Slavin S
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9277-9284. PubMed ID: 37202579
[TBL] [Abstract][Full Text] [Related]
18. Contribution of immune cells to bone metastasis pathogenesis.
He N; Jiang J
Front Endocrinol (Lausanne); 2022; 13():1019864. PubMed ID: 36246916
[TBL] [Abstract][Full Text] [Related]
19. Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.
Borchmann S; Selenz C; Lohmann M; Ludwig H; Gassa A; Brägelmann J; Lohneis P; Meder L; Mattlener J; Breid S; Nill M; Fassunke J; Wisdom AJ; Compes A; Gathof B; Alakus H; Kirsch D; Hekmat K; Büttner R; Reinhardt HC; Hallek M; Ullrich RT
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36223955
[TBL] [Abstract][Full Text] [Related]
20. Next Generation Natural Killer Cells for Cancer Immunotherapy.
Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
Front Immunol; 2022; 13():886429. PubMed ID: 35720306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
